2017-08-08 Assigned to DENALI THERAPEUTICS INC. reassignment DENALI
THERAPEUTICS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR …

A scalable synthesis of trifluoromethylated imidazo-fused N-heterocyles from heterocyclic
benzylamines using TFAA as trifluoromethylating reagent is presented. The reaction …

Late sodium current (I Na) inhibitors are a new subclass of antiarrhythmic agents. To
overcome the drawbacks, eg, low efficacy and inhibition effect on K+ current, of the FDA …

4,230,705 A 10/1980 Allen, Jr. et al. 4,242,515 A 12/1980 Trust et al. 4,244.953 A 1/1981
Trust et al. 4.326, 525 A 4, 1982 Swanson et al. 4,654,343 A 3/1987 Albright et al. 4,746,655 …

Provided herein are compounds and pharmaceutical com positions suitable as modulators
of hemoglobin, methods and intermediates for their preparation, and methods for their use in …

2012-08-20 Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC.
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …

The present invention provides novel 6-substituted 12.4 triazolo 4, 3-bipyridazines that are
agonists of Rev-Erb. These compounds, and pharmaceutical compositions com prising the …

2011-09-26 Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC.
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors …

(60) Provisional application No. 61/360,037, filed on Jun. disease states, including
cardiovascular diseases and diabe 30, 2010, provisional a lication No. 61/228.864 tes. In …

The present invention is directed to, in part, fused heteroaryl compounds and compositions
useful for preventing and/or treating a disease or condition relating to aberrant function of a …